Department of Health Management and Economics, Faculty of Health, Ilam University of Medical Sciences, Ilam.
Health Management and Economics Research Center, Health Management Research Institute, Iran University of Medical Sciences, Tehran.
Int J Surg. 2024 Jun 1;110(6):3338-3345. doi: 10.1097/JS9.0000000000001321.
Abdominal aortic aneurysm (AAA) is one of the most important cardiovascular diseases, especially in the elderly. People with this disease are at risk of rupture of the abdominal aorta and death. The present study was conducted with the aim of analyzing the cost-effectiveness of endovascular repair compared to open surgery in AAA patients in Iran.
A Markov chain model was developed based on the use of endovascular repair and open surgery. The base-case patient was defined as a 65-year-old man presenting with AAA diameter greater than 5 cm. The determination of costs was from the perspective of the public sector provider. QALY was used to calculate the effectiveness. Incremental cost-effectiveness ratio (ICER) and TreeAge software were used for cost-effectiveness analysis. The follow-up period was 10 years and the willingness to pay (WTP) was determined as three times the Gross domestic product (GDP) per capita.
At the end of year 10, the endovascular aneurysm repair (EVAR) strategy gained 1 318 313 559 Iranian Rial (IRR) (67 885.29$) in cost and 3.57 QALYs in effectiveness. In contrast, the use of the open surgery repair (OSR) strategy gained 1 186 761 858 IRR (61 111.16$) in cost and 3·32 QALYs in effectiveness. The incremental cost-effectiveness ratio, comparing EVAR versus OSR, was 53, 346, 3757 IRR (178.36$) per QALYs, which is lower than the proposed WTP, indicating that EVAR is more expensive and more effective. Based on the Monte Carlo simulation test, EVAR is the preferred strategy in 58.6% of the population.
Endovascular repair has a relative superiority compared to open surgery, and the probability of the effectiveness of endovascular repair compared to open surgery does not change with increasing willingness to pay.
腹主动脉瘤(AAA)是最重要的心血管疾病之一,尤其是在老年人中。患有这种疾病的人有腹主动脉破裂和死亡的风险。本研究旨在分析与伊朗 AAA 患者开放手术相比,血管内修复的成本效益。
根据使用血管内修复和开放手术,建立了一个马尔可夫链模型。基础病例患者被定义为 65 岁男性,AAA 直径大于 5cm。成本的确定是从公共部门提供者的角度出发的。QALY 用于计算有效性。使用增量成本效益比(ICER)和 TreeAge 软件进行成本效益分析。随访期为 10 年,意愿支付(WTP)定为人均国内生产总值(GDP)的三倍。
在第 10 年末,血管内动脉瘤修复(EVAR)策略在成本上获得了 1318313859 伊朗里亚尔(IRR)(67885.29 美元),在效果上获得了 3.57 QALY。相比之下,使用开放手术修复(OSR)策略在成本上获得了 1186761858IRR(61111.16 美元),在效果上获得了 3.32 QALY。EVAR 与 OSR 相比,增量成本效益比为 533463757IRR(178.36 美元)/QALY,低于提议的 WTP,表明 EVAR 更昂贵且更有效。基于蒙特卡罗模拟测试,EVAR 在 58.6%的人群中是首选策略。
与开放手术相比,血管内修复具有相对优势,并且血管内修复的效果与开放手术相比的概率不会随着意愿支付的增加而改变。